| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $822,233 ) |
| | 2024 | 2024 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | U01AI172733 | A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children | 000 | 1 | NIH | 3/15/2024 | $822,233 |
| | 2024 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 05 | 1 | HRSA | 11/29/2023 | $0 |
| | 2024 | 2021 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R21AI153936 | Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae | 000 | 2 | NIH | 4/24/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 Portland Ave | Rochester | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 04 | 1 | HRSA | 7/20/2023 | $0 |
| | 2023 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 03 | 1 | HRSA | 4/28/2023 | $0 |
| | 2023 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 01 | 1 | HRSA | 11/7/2022 | $0 |
| | 2023 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 02 | 1 | HRSA | 3/20/2023 | $0 |
| | 2023 | 2019 | ROCHESTER GENERAL HOSPITAL, THE | 1425 Portland Ave | Rochester | NY | 14621-3011 | MONROE | USA | C1232592 | School-Based Health Centers Capital Program | 04 | 1 | HRSA | 6/29/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,085,182 ) |
| | 2022 | 2022 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3011 | MONROE | USA | GE146233 | Community Project Funding/Congressionally Directed Spending - Non-Construction | 00 | 1 | HRSA | 7/18/2022 | $1,000,000 |
| | 2022 | 2022 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R03AI164138 | Immune biomarker discovery in children susceptible to recurrent otitis media | 000 | 2 | NIH | 6/22/2022 | $85,182 |
| | 2022 | 2019 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3011 | MONROE | USA | C1232592 | School-Based Health Centers Capital Program | 03 | 1 | HRSA | 2/11/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $289,717 ) |
| | 2021 | 2021 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R21AI153936 | Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae | 000 | 2 | NIH | 7/9/2021 | $200,000 |
| | 2021 | 2021 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R03AI164138 | Immune biomarker discovery in children susceptible to recurrent otitis media | 000 | 1 | NIH | 7/16/2021 | $89,717 |
| | 2021 | 2019 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3011 | MONROE | USA | C1232592 | School-Based Health Centers Capital Program | 02 | 1 | HRSA | 1/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $236,332 ) |
| | 2020 | 2020 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R21AI153936 | Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae | 000 | 1 | NIH | 8/21/2020 | $240,000 |
| | 2020 | 2018 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3011 | MONROE | USA | R03HD088909 | Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine | 000 | 2 | NIH | 1/10/2020 | -$3,668 |
|
| Issue Date FY: 2019 ( Subtotal = $100,000 ) |
| | 2019 | 2019 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3001 | MONROE | USA | C1232592 | School-Based Health Centers Capital Program | 00 | 1 | HRSA | 1/29/2019 | $100,000 |
| | 2019 | 2019 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3001 | MONROE | USA | C1232592 | School-Based Health Centers Capital Program | 01 | 1 | HRSA | 4/15/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $85,043 ) |
| | 2018 | 2018 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03HD088909 | Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine | 000 | 2 | NIH | 6/26/2018 | $85,043 |
| | 2018 | 2016 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI113649 | Immunogenicity of Moraxella catarrhalis vaccine candidates in children | 000 | 2 | NIH | 2/28/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = -$9,914 ) |
| | 2017 | 2017 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03HD088909 | Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine | 000 | 1 | NIH | 7/13/2017 | $84,828 |
| | 2017 | 2016 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 001 | 10 | NIH | 7/10/2017 | -$10,986 |
| | 2017 | 2016 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI117700 | Immune potentiation to improve neonatal and pediatric vaccines | 000 | 2 | NIH | 9/14/2017 | $0 |
| | 2017 | 2015 | ROCHESTER GENERAL HOSPITAL, THE | 1425 PORTLAND AVE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 000 | 9 | NIH | 7/7/2017 | $0 |
| | 2017 | 2013 | Rochester General Hospital, The | 1425 Portland Ave | Rochester | NY | 14621-3001 | MONROE | USA | C12CS25451 | Affordable Care Act (ACA) Grants for School-Based Health Centers Capital Program | 03 | 1 | HRSA | 1/24/2017 | -$83,756 |
|
| Issue Date FY: 2016 ( Subtotal = $680,470 ) |
| | 2016 | 2016 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI117700 | Immune potentiation to improve neonatal and pediatric vaccines | 000 | 2 | NIH | 4/4/2016 | $80,000 |
| | 2016 | 2016 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI113649 | Immunogenicity of Moraxella catarrhalis vaccine candidates in children | 000 | 2 | NIH | 4/5/2016 | $86,955 |
| | 2016 | 2016 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621 | MONROE | USA | R03AI117700 | Immune potentiation to improve neonatal and pediatric vaccines | 001 | 2 | NIH | 5/4/2016 | -$80,000 |
| | 2016 | 2016 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621 | MONROE | USA | R03AI117700 | Immune potentiation to improve neonatal and pediatric vaccines | 001 | 2 | NIH | 5/4/2016 | $80,000 |
| | 2016 | 2016 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 000 | 10 | NIH | 3/1/2016 | $585,306 |
| | 2016 | 2011 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | C12CS21984 | Affordable Care Act (ACA) Grants for School-Based Health Centers Capital Program | 04 | 1 | HRSA | 4/5/2016 | -$71,791 |
|
| Issue Date FY: 2015 ( Subtotal = $809,558 ) |
| | 2015 | 2015 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI117700 | Immune potentiation to improve neonatal and pediatric vaccines | 000 | 1 | NIH | 4/24/2015 | $80,000 |
| | 2015 | 2015 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R03AI113649 | Immunogenicity of Moraxella catarrhalis vaccine candidates in children | 000 | 1 | NIH | 5/4/2015 | $86,758 |
| | 2015 | 2015 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 000 | 9 | NIH | 1/29/2015 | $642,800 |
|
| Issue Date FY: 2014 ( Subtotal = $618,476 ) |
| | 2014 | 2014 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 001 | 8 | NIH | 7/9/2014 | $61,440 |
| | 2014 | 2014 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 000 | 8 | NIH | 3/15/2014 | $557,036 |
|
| Issue Date FY: 2013 ( Subtotal = $977,142 ) (Continued on the next page) |
| | 2013 | 2013 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | R01DC008671 | Immune Responses in Otitis Prone Children | 000 | 7 | NIH | 1/31/2013 | $501,333 |
| | 2013 | 2013 | ROCHESTER GENERAL HOSPITAL | 1425 PORTLAND AVENUE | ROCHESTER | NY | 14621-3001 | MONROE | USA | C12CS25451 | Affordable Care Act (ACA) Grants for School-Based Health Centers Capital Program | 0 | 1 | HRSA | 12/17/2012 | $447,957 |
|
